Quest Diagnostics: Wearables Strategy – The NEXT BIG Healthcare Disruption In The Making?

Quest Diagnostics Incorporated reported a solid start to fiscal year 2026, driven by organic revenue growth and operational improvements. The company delivered consolidated revenues of $2.9 billion in the first quarter, representing a 9.2% increase year-over-year, with organic growth contributing approximately 9%. Volume growth was robust at 10.9%, with major contributions from partnerships with Fresenius Medical Care and Corewell Health that accounted for about 7% of the growth. Excluding these collaborations, organic volume growth remained positive at 3.8%. The company experienced a slight decline in revenue per requisition by 1.3%, attributable to the mix effect from Fresenius and Corewell, but excluding these partnerships revenue per requisition grew by approximately 2.5%, driven primarily by an increased number of tests per requisition, supported by advanced diagnostics and consumer health expansion. Growth was broad-based across all customer channels, including physicians, hospitals, and consumer segments.

Our Report Structure: